BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.